PhRMA
AUGUST 5, 2022
The narratives being built around the Senate’s latest price setting proposal frame it as a bill intended to lower drug prices for patients and address rising inflation. But those narratives aren’t the facts. Here, we bust those myths.
Pharmacy Times
AUGUST 5, 2022
Patients can better understand the most current recommendations for breast cancer screening with the new NCCN Guidelines for Patients®: Breast Cancer Screening and Diagnosis.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 5, 2022
Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a takeover by Gilead Sciences in a $405 million deal. MiroBio was formed in 2019 to develop checkpoint agonist antibodies for autoimmune and inflammatory disorders that can be used to apply the “natural brakes” of the immune system.
Pharmacy Times
AUGUST 5, 2022
The FDA approved a new drug that treats unresectable and metastatic HER2-low breast cancer, giving patients with this new subtype a treatment beyond chemotherapy.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
AUGUST 5, 2022
Sanofi is making a €300 million investment in Chinese biotech Innovent as part of a collaboration to bring two new cancer therapies as quickly as possible to patients in the world’s second-largest pharma market. The deal – which includes an option on a second €400 million investment – will see the two companies jointly develop tusamitamab ravtansine (SAR408701), a CEACAM5-targeting antibody-drug conjugate (ADC), as well as a pegylated formulation of interleukin-2 codenamed SAR444245 in Chi
Pharmacy Times
AUGUST 5, 2022
Michael Ganio, PharmD, MS, BCPS, FASHP, senior director of pharmacy practice and quality at ASHP, discussed the declaration of monkeypox as a public health emergency.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
AUGUST 5, 2022
While the vaccines continue to provide critical, evidence-based protection against the coronavirus, rare cases of myocarditis and pericarditis have been reported.
Pharmaceutical Technology
AUGUST 5, 2022
Amgen has signed a definitive agreement to acquire biopharmaceutical company ChemoCentryx for $52 for each share in cash or a total enterprise cost of nearly $3.7bn. ChemoCentryx focuses on orally administered therapeutics for the treatment of inflammatory disorders, autoimmune ailments and cancer. For discovering, developing and marketing such treatments, the company targets the chemokine and chemoattractant systems.
Pharmacy Times
AUGUST 5, 2022
Older individuals who were exposed to any amount of light while sleeping were significantly more likely to be obese, have high blood pressure, and have diabetes.
European Pharmaceutical Review
AUGUST 5, 2022
Clinigen Healthcare is recalling three batches of Mexiletine hydrochloride hard capsules, indicated for the treatment of documented arrhythmias, due to a potential risk of under- or overdose, which could have consequences for the safety of patients. The Class 1 Medicines Recall Notification was published by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
AUGUST 5, 2022
A recent study found that 61% of otherwise healthy Black and Hispanic adolescents have low vitamin D levels, which continues to drop with age.
PharmExec
AUGUST 5, 2022
Court Horncastle discusses how his career led him to work with treating COPD and asthma.
Pharmacy Times
AUGUST 5, 2022
Xenia Tigno, PhD, and Reshma Jagsi, MD, DPhil, discuss how the pandemic impacted women’s careers in medical research and other medical fields.
Pharmaceutical Technology
AUGUST 5, 2022
The European Commission (EC) has granted approval for Merck (MSD outside the US and Canada) and AstraZeneca ’s Lynparza (olaparib) as monotherapy or along with endocrine therapy for the adjuvant treatment in adults with high-risk, early-stage breast cancer. The treatment is indicated for people with germline BRCA1/2 mutations (gBRCAm) and have human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
AUGUST 5, 2022
Study finds that only 19.6% of US adults have high cardiovascular health, whereas 62.5% have moderate health and 17.9% have low.
Pharmaceutical Technology
AUGUST 5, 2022
Gilead Sciences has signed a definitive agreement for the acquisition of the complete outstanding share capital of MiroBio in a deal valued at nearly $405m in cash, subject to necessary adjustments. With the acquisition, Gilead will gain access to the discovery platform and complete line of immune inhibitory receptor agonists of MiroBio. The scientific approach of MiroBio for immune balance restoration to treat autoimmune diseases complements the inflammation research and development works of Gi
Pharmacy Times
AUGUST 5, 2022
The move would help ensure timely access to vaccination following the declaration of monkeypox as a public health emergency.
Pharmaceutical Technology
AUGUST 5, 2022
The diabetic macular oedema (DME) space recently witnessed a new approval; the US Food and Drug Administration (FDA) announced the approval of Coherus’ Cimerli (ranibizumab-eqrn; FYB201), a vascular endothelial growth factor (VEGF) inhibitor therapy. Cimerli is a biosimilar of Lucentis (ranibizumab) and has been granted 12 months of interchangeability exclusivity across five different retinal diseases: DME, diabetic retinopathy (DR), neovascular (wet) age-related macular degeneration (AMD), myop
Pharmacy Times
AUGUST 5, 2022
Results also show that nearly half are not sure whether a vaccine exists, and a large majority know that the disease spreads through close contact.
pharmaphorum
AUGUST 5, 2022
Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. Such inorganic growth is no longer viable, argues Pervaise Khan, Accenture’s UK Life Sciences Lead. The pace of innovation in biopharma has rocketed over the last two years, with vaccines, new antivirals, and therapies delivered at an unprecedented pace.
Pharmacy Times
AUGUST 5, 2022
Key opinion leaders discuss common narratives and concerns regarding a variety of vaccines and share successful strategies to overcome vaccine reluctance.
Pharmaceutical Commerce
AUGUST 5, 2022
A look into the effectiveness of data processing pipelines.
Pharmacy Times
AUGUST 5, 2022
The panel of pharmacists discuss the immunization tracker registry and emphasize utilizing this tool in preparation for the coming flu season.
Pharmaceutical Commerce
AUGUST 5, 2022
Five strategies to help pharma companies improve their return on investment from adherence-promoting initiatives and drive positive health outcomes for patients.
Pharmacy Times
AUGUST 5, 2022
Study is the first to use an artificial intelligence algorithm to break down visual field loss in new-onset glaucoma cases among population groups in the United States.
Pharma Times
AUGUST 5, 2022
Better Meds is already removing paper forms and manual processes from NHS Trust’s system
Pharmacy Times
AUGUST 5, 2022
Daptomycin for injection (Cubicin) is indicated for the treatment of complicated skin and skin structure infections and Staphylococcus aureus bloodstream infections.
Pharma Times
AUGUST 5, 2022
Partnership will accelerate development of oncology medicines and expand presence in China
Pharmacy Times
AUGUST 5, 2022
Total Cleanse Uric Acid helps to reduce uric acid levels in the body and help support a greater level of comfort in the joints.
Pharmaceutical Technology
AUGUST 5, 2022
The development of therapeutics for transmissible spongiform encephalopathies (TSEs) continues to be challenged by the complex nature of these diseases. Also referred to as prion diseases, TSEs are rare and fatal neurodegenerative conditions. As per the prevailing prion theory, a misfolded version of a normal cell-surface protein acts as the chief infectious agent.
Pharmacy Times
AUGUST 5, 2022
We couldn't get to where we are at today without your amazing support!
The Thyroid Pharmacist
AUGUST 5, 2022
Before I received my Hashimoto’s diagnosis, I used to start each day with a protein smoothie. In some ways, this was a very positive habit; but in other ways, it was very detrimental to my health, and I didn’t even know it. Protein is an essential macronutrient and helps us to build up our body, to ensure that all vital processes are taking place. Protein is an important source of amino acids such as glutamine and L-tyrosine, which repair gut cells and create thyroid hormones, respectively.
European Pharmaceutical Review
AUGUST 5, 2022
A single injection of the investigational L9LS monoclonal antibody (mAb) has been found to be safe and highly protective in US adults exposed to the malaria parasite. The results of the Phase I US National Institutes of Health (NIH) study were published in The New England Journal of Medicine. In 2020, the World Health Organization (WHO) estimated that 240 million people had malaria, the mosquito-borne disease spread by Plasmodium parasites, and that it caused about 627,000 deaths.
The Honest Apothecary
AUGUST 5, 2022
Motivation, like any resource, needs replenishment. If you manage a pharmacy you likely have some sort of inventory replenishment system. Without this, your stock would disappear and your whole business would come to a grinding halt. We all keep an eye on our gas tank. For me, anything below half a tank means a stop to refill at some point that day.
Expert insights. Personalized for you.
130 
Let's personalize your content